In a phase 3 trial of 786 patients with early-stage TNBC, adding carboplatin to adjuvant EC-T improved disease-free survival (HR 0.66) and overall survival (HR 0.39) at median 4.52 years, but grade 3-4 adverse events rose (49.9% vs 38.7%).
RCTn = 786 patients
Chen et al. Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial